Latest Breaking News On - Ico therapeutics inc - Page 5 : comparemela.com
iCo Therapeutics Inc Announces Closing of Upsized Subscription Receipt Private Placement
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
iCo Therapeutics Inc Announces Upsized Subscription Receipt Private Placement
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
iCo Therapeutics Inc : iCo Therapeutics, Inc Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
iCo Therapeutics Inc Announces Warrant Exercises
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
iCo Therapeutics Inc.: iCo Therapeutics Inc: Unaware of Any Material Change
. (TSXV: ICO) (OTCQB: ICOTF) (
iCo or the
Company ). At the request of IIROC, iCo Therapeutics Inc. (the Company ) wishes to confirm that the Company s management is unaware of any material change in the Company s operations that would account for the recent increase in market activity.
About iCo Therapeutics
iCo is Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases.
For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.